Biogen Inc.

▲ Bull Case

• ◆SC starting-dose approval + market expansion = Ozempic-style adoption curve: Aug 24, 2026 PDUFA approval would eliminate the infusion center bottleneck, expanding the eligible Leqembi patient population 3-5x (from ~500K infusion-accessible to 2-3M home-injectable); combined with adoption of $200-400 blood-based amyloid diagnostics (replacing $5,000+ PET scans), the effective addressable market grows another 3-4x; Leqembi BIIB share could reach $3-3.5B by FY2030 vs. consensus $1-2B.
• ◆Reata intangible amortization burn-off provides $700M/yr GAAP EPS mechanical tailwind: Over 10-15 years, ~$10-12B in Reata intangibles amortize off; GAAP EPS converges toward non-GAAP EPS without any operational improvement; supports valuation re-rating as GAAP becomes consistent with non-GAAP.
• ◆Felzartamab Phase 3 readouts in 2027 + Skyclarys $1B peak + Apellis Syfovre integration: Three independent positive optionality drivers; pipeline option value not reflected in current 12.3x multiple; even single Phase 3 success in IgA nephropathy adds $1-2B NPV.

▼ Bear Case

• ◆CRL outcome on Aug 24, 2026 triggers -20 to -35% stock reaction: FDA voluntary holds on infusion drugs are not rare; a CRL would delay SC approval 6-12 months and create $130-160/share intrinsic value via P/E compression + EPS cut; the market knows this is the dominant outcome variable.
• ◆APOE4 safety restrictions expand; effective TAM contracts: Real-world ARIA (amyloid-related imaging abnormality) data could trigger FDA label expansion of APOE4 contraindications; if homozygous PLUS heterozygous APOE4 carriers are restricted, eligible population halves; Leqembi peak revenue capped at $2-3B regardless of SC approval status.
• ◆MS cliff accelerates; pipeline doesn't fill gap: Tysabri US biosimilar entry (expected 2026-2027) plus Ocrevus generic pressure could drive -20-25%/yr MS decline; combined with Leqembi growth disappointment, revenue gaps for 3-4 years; EPS stagnant or declining through FY2029.

“The debate is binary and time-bounded: will the FDA approve Leqembi SC starting-dose on August 24, 2026? Bulls (approval probability ~70%) cite Phase 3 CLARITY AD data supporting SC route, SC maintenance dose already approved October 2025, FDA Priority Review status, and no AdCom required. Bears (approval probability ~50-60%) point to ARIA safety remaining a real concern and FDA caution on infusion-to-SC transitions in CNS drugs, making CRL a credible 30-40% outcome. The resolution happens in less than three months, making this one of the cleanest event-driven setups in large-cap healthcare.”

• ◆Leqembi SC starting-dose PDUFA — August 24, 2026 (THE catalyst; approval = +30-50%; CRL = -25-35%)
• ◆Q2 2026 earnings: Leqembi quarterly revenue (August 2026; pre-PDUFA evidence of SC maintenance dose ramp)
• ◆China Leqembi approval (H2 2026/2027; first major OUS approval; trial run for global launch)
• ◆Felzartamab Phase 3 IgA nephropathy readout (2027; pipeline option value crystallization)
• ◆Medicare Part D full coverage launch (January 2027; removes Part B prior-auth friction)

• ◆Leqembi SC PDUFA CRL (MEDIUM probability ~30%; HIGH impact — bear case materializes; stock $130-160)
• ◆APOE4 safety label expansion (MEDIUM probability; HIGH impact — TAM contraction; Leqembi peak halved)
• ◆MS cliff accelerates >20%/yr (MEDIUM probability; HIGH impact — revenue gap widens for 3-4 years)
• ◆Apellis deal value destruction (MEDIUM probability; MEDIUM impact — distraction + leverage increase)
• ◆Pipeline failure: Felzartamab Phase 3 (MEDIUM probability; LOW-MEDIUM impact — option value erased)
• ◆No buyback / no dividend (ongoing; LOW impact — limits capital return; structural negative for value investors)